- Home
- NXJ vs LRMR Comparison
NXJ vs LRMR Comparison
Compare NXJ & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXJ
- LRMR
- Stock Information
- Founded
- NXJ 1999
- LRMR N/A
- Country
- NXJ United States
- LRMR United States
- Employees
- NXJ N/A
- LRMR N/A
- Industry
- NXJ Finance/Investors Services
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- NXJ Finance
- LRMR Health Care
- Exchange
- NXJ Nasdaq
- LRMR Nasdaq
- Market Cap
- NXJ 520.4M
- LRMR 426.9M
- IPO Year
- NXJ N/A
- LRMR N/A
- Fundamental
- Price
- NXJ $12.24
- LRMR $6.18
- Analyst Decision
- NXJ
- LRMR Strong Buy
- Analyst Count
- NXJ 0
- LRMR 8
- Target Price
- NXJ N/A
- LRMR $19.63
- AVG Volume (30 Days)
- NXJ 74.9K
- LRMR 744.4K
- Earning Date
- NXJ 01-01-0001
- LRMR 10-30-2024
- Dividend Yield
- NXJ 3.27%
- LRMR N/A
- EPS Growth
- NXJ N/A
- LRMR N/A
- EPS
- NXJ N/A
- LRMR N/A
- Revenue
- NXJ N/A
- LRMR N/A
- Revenue This Year
- NXJ N/A
- LRMR N/A
- Revenue Next Year
- NXJ N/A
- LRMR N/A
- P/E Ratio
- NXJ N/A
- LRMR N/A
- Revenue Growth
- NXJ N/A
- LRMR N/A
- 52 Week Low
- NXJ $10.06
- LRMR $3.09
- 52 Week High
- NXJ $12.24
- LRMR $13.68
- Technical
- Relative Strength Index (RSI)
- NXJ 35.25
- LRMR 34.63
- Support Level
- NXJ $12.21
- LRMR $5.92
- Resistance Level
- NXJ $12.51
- LRMR $6.60
- Average True Range (ATR)
- NXJ 0.08
- LRMR 0.69
- MACD
- NXJ 0.00
- LRMR -0.32
- Stochastic Oscillator
- NXJ 13.33
- LRMR 4.45
About NXJ Nuveen New Jersey Qualified Municipal Fund
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.